Jakafi?

Jakafi is a medication used to treat specific conditions such as myelofibrosis, polycythemia vera, and graft-versus-host disease [1].

What is Jakafi used for?

Jakafi, also known by its generic name ruxolitinib, is approved for several indications. It is prescribed for patients with intermediate or high-risk myelofibrosis, a serious bone marrow disorder. It is also used to treat polycythemia vera, a condition where the body makes too many red blood cells, in patients who have had an inadequate response to or are intolerant of hydroxyurea. Additionally, Jakafi is used for acute graft-versus-host disease after stem cell transplantation, for patients aged 12 years and older [1].

How does Jakafi work?

Jakafi functions as a Janus kinase (JAK) inhibitor [1]. Specifically, it targets JAK1 and JAK2 enzymes, which are involved in signaling pathways that regulate blood cell growth and immune function. By inhibiting these enzymes, Jakafi helps to reduce inflammation and the overproduction of certain blood cells, thereby alleviating symptoms associated with the conditions it treats [1].

When does the patent for Jakafi expire?

The patent protection for Jakafi is complex and has been the subject of litigation. While original patent expiry dates are often cited, the exact timeline for when generic versions can enter the market can be affected by various legal challenges and exclusivities. Information regarding specific patent expiry dates for Jakafi can be found through resources like DrugPatentWatch.com [2].

What are the main side effects of Jakafi?

Common side effects of Jakafi can include a low number of blood cells (anemia, thrombocytopenia, neutropenia), diarrhea, fatigue, and shortness of breath [1]. More serious side effects may occur, and patients should discuss potential risks with their healthcare provider.

Can biosimilar versions of Jakafi become available?

The development and availability of biosimilar versions of Jakafi depend on patent expirations and regulatory pathways. Once patents expire and exclusivities are no longer in effect, companies may pursue the development and approval of biosimilar products, offering potentially lower-cost alternatives [2].

Who manufactures Jakafi?

Jakafi is manufactured by Incyte Corporation [1].

Sources:
[1] https://www.jakafihcp.com/
[2] https://drugpatentwatch.com/